Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Glaukos Corp (GKOS)

Glaukos Corp (GKOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis Business Wire - Thu Jun 25, 6:00AM CDT

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 142.57 (+3.49%)
Glaukos Announces Participation in Upcoming Investor Conferences Business Wire - Tue May 12, 6:00AM CDT

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 142.57 (+3.49%)
Glaukos: Q1 Earnings Snapshot AP - Wed Apr 29, 3:52PM CDT

Glaukos: Q1 Earnings Snapshot

GKOS : 142.57 (+3.49%)
Glaukos Announces First Quarter 2026 Financial Results Business Wire - Wed Apr 29, 3:05PM CDT

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 142.57 (+3.49%)
Glaukos Reports Tomorrow With Epioxa Launch Metrics Still Unknown Barchart - Tue Apr 28, 4:14PM CDT

Barchart Research What to Expect from GKOS Earnings GKOS Generated April 28, 2026 Current Price $119.63 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 9.55% Glaukos Reports Tomorrow With...

GKOS : 142.57 (+3.49%)
Glaukos Announces the Release of its 2025 Sustainability Report Business Wire - Thu Apr 16, 6:00AM CDT

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced...

GKOS : 142.57 (+3.49%)
Glaukos Receives Permanent J-code for Epioxa™ Business Wire - Wed Apr 15, 3:05PM CDT

New J-code for Epioxa ™ , J2789, set to become effective July 1, 2026

GKOS : 142.57 (+3.49%)
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29 Business Wire - Wed Apr 8, 6:00AM CDT

Conference Call and Webcast Scheduled for 1:30 p.m. PT

GKOS : 142.57 (+3.49%)
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting Business Wire - Mon Apr 6, 6:00AM CDT

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced...

GKOS : 142.57 (+3.49%)
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care Business Wire - Thu Mar 19, 6:00AM CDT

Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease

GKOS : 142.57 (+3.49%)

Barchart Exclusives

Buy This Dividend King with a 54-Year Streak Before July 9 Barchart - Thu Jun 25, 6:30PM CDT
A 54-year dividend growth streak gives PepsiCo credibility. But upcoming earnings will show if the streak will continue. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.